title: Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans.
abstract: While the parenteral iron-chelating agent desferrioxamine B has anti-malarial activity in humans, the usefulness of an orally active chelator for this indication has not been investigated previously in vivo. We conducted a prospective, double-blind, placebo-controlled, cross-over trial of deferiprone (L1; CP20; 1,2-dimethyl-3-hydroxypyridin-4-one) in 25 adult Zambians with asymptomatic Plasmodium falciparum parasitemia. Deferiprone was administered daily for three or four days in divided doses of 75 or 100 mg/kg of body weight, dosages that are effective for treating iron overload. No reduction in asexual intra-erythrocytic parasites was observed during or after deferiprone treatment. The mean peak plasma concentration of deferiprone (108.9 +/- 24.9 micromol/L) achieved was within the range demonstrated to inhibit the growth of P. falciparum in vitro, but the systemic exposure as determined by the 24-hr plasma concentration-time curve would not be predicted inhibit growth in vivo. No evidence of deferiprone-associated hematological toxicity was noted in this short-term study of these subjects, all of whom had clinical evidence of normal body iron stores. Because of the risk of neutropenia and other adverse effects with higher doses or prolonged use of the chelator, additional trials of deferiprone as a sole anti-malarial agent would not seem to be justified. In contrast, further efforts are needed to develop other orally active iron-chelating agents specifically for their anti-malarial action.
authors.affiliation: Pennsylvania State University Hershey Medical Center, USA.
authors.forename: P E
authors.initials: PE
authors.lastname: Thuma
authors.forename: N F
authors.initials: NF
authors.lastname: Olivieri
authors.forename: G F
authors.initials: GF
authors.lastname: Mabeza
authors.forename: G
authors.initials: G
authors.lastname: Biemba
authors.forename: D
authors.initials: D
authors.lastname: Parry
authors.forename: S
authors.initials: S
authors.lastname: Zulu
authors.forename: F F
authors.initials: FF
authors.lastname: Fassos
authors.forename: R A
authors.initials: RA
authors.lastname: McClelland
authors.forename: G
authors.initials: G
authors.lastname: Koren
authors.forename: G M
authors.initials: GM
authors.lastname: Brittenham
authors.forename: V R
authors.initials: VR
authors.lastname: Gordeuk
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019540:Area Under Curve; D018592:Cross-Over Studies; D000077543:Deferiprone; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D018512:Parasitemia / Q000188:drug therapy* / Q000378:metabolism; D011446:Prospective Studies; D011728:Pyridones / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone